Recursion Pharmaceuticals (RXRX) Capital Expenditures (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Capital Expenditures came in at $258000.0 in Q1 2026, down 85.92% YoY from $1.8 million in Q1 2025, and up 104.94% on a QoQ basis from -$5.2 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Capital Expenditures (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Capital Expenditures data on file, last reported at $258000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 85.92% year-over-year to $258000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.6 million (down 117.74% YoY) and the FY2024 annual result came in at $13.7 million, up 14.55% from the prior year.
- Capital Expenditures improved to $258000.0 in Q1 2026, from -$5.2 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $12.0 million in Q4 2023 to a low of -$6.1 million in Q2 2024.
- A 5-year average of $1.6 million and a median of $258000.0 in 2026 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures slumped 2976.79% — and 2024, when it surged 197566.67%.
- Tracing RXRX's Capital Expenditures over 5 years: stood at -$2.5 million in 2022, then surged by 577.82% to $12.0 million in 2023, then slumped by 89.14% to $1.3 million in 2024, then sank by 502.54% to -$5.2 million in 2025, then surged by 104.94% to $258000.0 in 2026.
- The last three Capital Expenditures figures came in at $258000.0 (Q1 2026), -$5.2 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 44,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44,000.00 |
| Jun 30, 2026 | 44,000.00 |
| Mar 31, 2026 | 258,000.00 |
| Mar 31, 2026 | 258,000.00 |
| Dec 31, 2025 | -5.23 Mn |
| Dec 31, 2025 | -5.23 Mn |
| Sep 30, 2025 | 4.96 Mn |
| Sep 30, 2025 | 4.96 Mn |
| Jun 30, 2025 | -1.57 Mn |
| Jun 30, 2025 | -1.57 Mn |
| Mar 31, 2025 | 1.83 Mn |
| Mar 31, 2025 | 1.83 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 11.85 Mn |
| Sep 30, 2024 | 11.85 Mn |
| Jun 30, 2024 | -6.10 Mn |
| Jun 30, 2024 | -6.10 Mn |
| Mar 31, 2024 | 6.65 Mn |
| Mar 31, 2024 | 6.65 Mn |